1. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study 
Dr Cheryl Cohen, PhD, Claire von Mollendorf, MD, Linda de Gouveia, NDMedTech, Sarona Lengana, MD, Susan Meiring, MD, Vanessa Quan, MD, Arthermon Nguweneza, MSc, David P Moore, MD, Gary Reubenson, MD, Mamokgethi Moshe, MD, Prof Shabir A Madhi, PhD, Prof Brian Eley, MD, Ute Hallbauer, MD, Heather Finlayson, MD, Sheeba Varughese, MD, Prof Katherine L O'Brien, MD, Elizabeth R Zell, MSc, Prof Keith P Klugman, PhD, Cynthia G Whitney, MD, Anne von Gottberg, PhD 
The Lancet Global Health 
Volume 5, Issue 3, Pages e359-e369 (March 2017)
DOI: /S X(17)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions

2. Figure
Bar chart showing the serotype of invasive pneumococcal disease and vaccination status of children eligible to receive PCV13 through the routine immunisation programme in South Africa (born after August, 2011)
Bars show the number of children aged 16 weeks or older (A) not infected with HIV (total n=240) and (B) infected with HIV (total n=75), and the number of doses of PCV13 received. *Not subtyped further. †Other non-vaccine serotype confirmed with PCR. ‡Unknown serotypes occurred either because an isolate was not available or because only serogroups could be ascertained with PCR.
The Lancet Global Health 2017 5, e359-e369DOI: ( /S X(17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license Terms and Conditions